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Resumen 
Hemos  comprobado  el  efecto in  vivo del p-sitosterol en un modelo 
de dermatitis  de contacto  por hipersensibilidad  retardada  (DTH). 
Este  compuesto  fue  igualmente  ensayado  en  modelos  de 
liberation  de  eicosanoides  en  leucocitos  polimorfonucleares  de 
rata  y  plaquetas  humanas estimuladas  con  ionoforo A23817 en 
incubaciones  de  15  min.  El  compuesto  reduce  de  manera 
significativa  el  edema inducido por oxazolona a  las 24 horas,  sin 
mostrar efecto alguno sobre las enzimas de la  cascada del  acido 
araquidonico implicadas en la  iniciacion del fenomeno  inflamatorio, 
en  las  condiciones  descritas.  Los  resultados  indican  que  este 
compuesto  puede  modular  el  edema  mediado  por  respuesta 
celular  sin  ningun  efecto  a  corto  plazo  en  la  cascada del  acido 
araquidonico.  La  ubicuidad  del  p-sitosterol  puede  explicar,  y 
predecir, el  efecto de muchos  extractos vegetales en este modelo 
in  vivo, y por  tanto estoe dato puede  ser de ayuda  en procesos  de 
"de-replicacion". 
Palabras  clave:  p-Sitosterol;  hipersensibilidad  retardada; 
dermatitis de  contacto; eicosanoides 
Abstract 
The  in  vivo  effect  of  p-sitosterol  in  a  model  of  delayed-type 
hipersensitivity  (DTH)  contact  dermatitis  was tested.  The compound 
was  also  tested  in  intact,  A23817  stimulated  rat-peritoneal 
polymorphonuclear leukocytes and human  platelets for the inhibition of 
eicosanoids release in  15 min incubations. The  compound  reduced in  a 
significant  manner the  oedema induced  by  oxazolone  only  at  24  h, 
without  any  effect  on  the  enzymes  of  the  arachidonate  pathway 
involved  in  the  onset  of  the  inflammatory  process  in  the  conditions 
above  described. The  results indicate that this compound  can modulate 
a  cell-mediated oedema without any short term  in  vitro  effect on the 
arachidonate pathway  of intact cells. The  ubiquity of  this compound  can 
explain,  and  predict,  the  effect  of many plant  extracts  in  this  in  vivo 
model, and  so  this data could be  of  help in dereplication processes. 
Key  words  p-Sitosterol;  delayed-type  hypersensitivity;  contact 
dermatitis; eicosanoids. 
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Introduction 
(3-Sitosterol  is  one  of  the  most  ubiquitous 
substances  in  plant extracts.  In the last 10 years 
the biological  role  of phytosterols  in  human and 
animal  health  has  been  established,  with  an 
emphasis  in  their  in  vitro  and  in  vivo  immune 
modulatory activity  (1,  2).  There are  references 
of  the  immunomodulatory  properties  of  (3-
sitosterol  and  its  glucosides  (3,  4).  It  also  has 
been  reported  that  it  has  in  vivo  topical  anti-
inflammatory  properties  in  the  acute  TPA-
induced  ear  oedema  in  mice  but  not  in  the 
chronic  one  (5).  However  it  inhibits  leukocyte 
infiltration  in  both  models.  Little  more is  known 
about the  biochemical  mechanism of this  anti-
inflammatory activity.  Mat AN and Houghton  (6) 
showed  that  this  compound  inhibits  soy  5-
lipoxigenase In  vitro.  Keratinocytes also respond 
to skin  irritation  and injury  by means  of a rapid, 
but transient activation  of arachidonic acid  (AA) 
metabolism through the lipoxigenase (LOX) and 
cyclooxigenase  (COX)  pathways  (7).  Topical 
inflammation  involves  some  chemotactic  and 
chemokinetic agents produced from arachidonic 
acid  by LOX  activity,  like  12-hydroxy-6,8,11,14-
eicosatetraenoic  acid  (12(S)-HETE)  (8)  from 
platelets  and  5-hydroxy-6,8,11,14-
eicosatetraenoic  acid  (5(S)-HETE)  and 
leukotriene  B4  (LTB4)  from  polymorphonuclear 
leukocytes  (PMNL).  They  contribute,  together 
with the prostaglandins (PGs) and  thromboxanes 
(TXs)  produced  by  the  COX  activity,  to  the 
inflammatory  response  of  the  skin.  After  this 
initial  phase, LTB4  is the responsible  for the long-
term  maintenance  of the  inflammation,  and for 
this  reason,  in  the  last  years  there  was  an 
increasing  interest  on the  LTB4 role  and now  it 
seems  that  it  surpass the idea of a chemotactic 
agent  (9).  Therefore,  an  understanding  of  the 
effect  of  this  compound  on  the  enzymatic 
pathways  involved  in  the  eicosanoids 
biosynthesis  is  important.  Thus we decided  to 
explore  its  anti-inflammatory  effects  on  in  vitro 
models  of LTB4  (from 5-lipoxigenase), 12-HHTrE 
(from cycloxigenase-1), and 12-HETE (from  12-
lipoxigenase) release by mammalian  intact cells, 
as  well as  on  an  in vivo model  of  contact  delayed 
hypersensitivity  to  check its  ability  to  modulate 
immune  mediated  topical  inflammatory 
processes. 
Material and  Methods 
Animals 
Female  Wistar  rats  (180-200  g)  and  female 
Swiss  mice  (25-30  g)  were  provided  by  the 
animal  facility  of  the  Faculty  of  Pharmacy 
(University  of  Valencia).  They were  housed  in 
standard  environmental  conditions.  The 
institutional  Ethical  Committee of the  Faculty  of 
Pharmacy,  University  of  Valencia  (Spain) 
approved  all  in  vivo  experiments,  which  were 
performed  according  to  the  guidelines 
established  by  the  European  Union  on  Animal 
Care  (CEE  Council 86/609). 
Cells 
Human  platelets  were  obtained  by  diluting 
human  buffy-coats  (obtained  at  the  Centre  de 
Transfusions  de  la  Generalitat  Valenciana, 
Valencia, Spain) with PBS  (1:3) and centrifuging 
twice  (300  x  g,  10  min),  discarding  the  pellets 
and keeping the platelet rich  supernatants. After 
centrifugation,  the  resulting  pellet  was washed 
twice (1000 x g,  10 min) and  finally resuspended 
in  Hank's  Balanced  Salt  Solution  (HBSS)  with 
Ca2+ (1  mM)  and Mg2+ (0.5 mM). The  differential 
counting was  done by Coulter Counter (Sysmex 
D-800).  Semi-quantitative  estimation  of  the 
platelets'  viability  was  performed  before  each 
experiment  by  fluorescence  microscopy 
(Nikon®,  Japan)  staining  with  acridine 
orange/ethidium bromide  solution. 
Rat  peritoneal  polymorphonuclear  leukocytes 
(PMNLs)  were  harvested  by  intraperitoneal 
injection  of glycogen (1  mg/g body weight in  10 
mL  of PBS, 37  °C) and  washed  by centrifugation 
(10 min, 300  x g, room  temperature, twice). 
The  cell  viability  of  the  elicited  rat  peritoneal 
PMNLs and  human  leukocytes  was  assessed 
before each experiment  using  the  Trypan  blue 
exclusion test.  Only harvested cells with viability 
greater  than 95%  were  used. 
Chemicals 
Boswellia  serrata  standardised  resin  was 
obtained  from  H15 tablets  (Gufic  Chemicals®, 
India).  (3-sitosterol,  isolated  from  Ranunculus 
sceleratus  L.  as  described  previously  (10). 
Dexamethasone  and oxazolone  were  purchased 
from  Sigma®  (St.  Louis,  USA).AII  other 
chemicals  were  of  the  highest  available 
analytical  grade  and  purchased  from  Sigma® 
(St.  Louis,  USA)  and  Merck®  (Darmstadt, 
Germany).  Solvents  (HPLC  grade)  were 
provided by JT  Baker®  (Deventer, Holland). 
Analytical high-performance  liquid 
chromatography  (HPLC)-diode  array  detector 
(DAD) 
HPLC-DAD  analysis was  performed on a Merck-
Hitachi® system equipped with a Pump  L-6200, 
L-7455 Diode Array Detector and Auto Sampler 
L-7200,  injection valve (Reodyne®), loop of 100 
|.iL,  precolumn Lichrospher® C18 (4  x 4 mm, 5 
urn,  Merck®),  and  column  Lichrospher®  C18 
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(250  x  4  mm,  5  urn,  Merck).  The  data  were 
collected and processed  with the software HSM-
7000  (Merck-Hitachi®). 
HPLC-DAD  for eicosanoids analysis was  carried 
out  using  an  isocratic  elution  program  with 
methanol/H2O  (74:26)  +  trifluoroacetic  acid 
(0.007%) as  eluent  at a  flow  rate 1  mL/min  (11). 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide  (MTT)  assay 
The  assay  described  by  Mosmann  (12)  was 
used  as  a  criterion  of  cytotoxicity  for  human 
leukocytes.  Briefly,  106 cells  were preincubated 
at 37  °C  for 30 min  with Dulbeccos' PBS, pH  7.4, 
containing  the  extracts  at  concentrations  up to 
200  ug/mL  Controls  received  vehicle  and 
correspond to  100% viability.  The yellow water-
soluble substrate MTT  is converted by living cells 
into  a  dark  blue  formazan  product  that  is 
insoluble  in  water. The coloured metabolite was 
dissolved  in  DMSO in  an  ultrasonic  bath  and 
measured  using  a  Labsystem  Multiskan 
MCC/340  plate reader, at 490  nm. 
Determination  of  5-lipoxygenase  (5-LOX) 
activity 
We  followed the protocol established by Safayhi 
et al.  (11).  Rat peritoneal PMNLs  (5  x  106) were 
resuspended  in  1  ml  PBS (with  glucose,  1  g/l) 
and pre-incubated for 5 min with the extracts or 
reference  compounds  at  37  °C.  Then,  the 
reaction  was  started  by  addition  of  ionophore 
A23187  and  Ca2+  (1.9  nM and  1.8  mM final 
concentrations,  respectively).  After 5  min  at  37 
°C,  the reaction was stopped with  1  mL  of cold 
methanol  /  1N-HCI  (97:3),  and  500  pmol  of 
prostaglandin  B2  (PGB2)  were  added  as  an 
internal standard. After  centrifugation (10000  x g, 
5  min,  0 °C),  the samples were applied to C18 
SPE columns (100  mg),  pre-conditioned with  1 
mL  of methanol and 1  mL  of  water. The  columns 
were washed with  1  mL  of water and  1  mL  of 
25%  methanol.  The  5-LOX  metabolites  5(S)-
HETE, LTB4, 6-frar?s-leukotriene B4 and 6-trans-
12-epi-leukotriene  B4  (LTB4  all-frans-isomers) 
were  extracted  with  300  \iL  of  methanol  and 
analysed  by  high  performance  liquid 
chromatography (HPLC-DAD). 
Determination  of  cyclooxygenase-1/12-
lipoxygenase  (COX-1/12-LOX)  activity 
The  assay  is  based on the protocol proposed by 
Safayhi et  al.  (13).  Aliquots  of 80 x  106 human 
platelets  were  pre-incubated  for  5  min  with 
extracts or reference compounds  at 37°C. Then 
the reaction was  started by  addition of ionophore 
A23187  (1.9 \xM final  concentration). After 1  min 
the  reaction  was  stopped  with  1  mL of  cold 
methanol/1N HCI (97:3),  and 500 pmol of PGB2 
were  added  as  internal  standard.  After 
centrifugation  (10000  x  g  for  10  min)  the 
supematants  were  pooled,  subjected  to  SPE 
above  and  analysed by HPLC-DAD  as  described 
in  the  previous  assay.  The  measured 
metabolites  were  12(S)-hydroxyheptadeca-
5Z,8£,10£-trienoic acid  (12(S)-HHTrE) from the 
COX-1  pathway, and 12(S)-HETE from the  12-
LOX  pathway. 
Oxazolone-induced  contact-delayed 
hypersensitivity (DTH)  mouse  ear  edema 
The  oxazolone-induced DTH  test was  performed 
according  to  Recio  et  al.  (14).  Briefly,  female 
mice were sensitised  by  topical  application  on 
the  shaven ventral  abdomen of 50 jaL  of a 2% 
(w/v)  solution  of  oxazolone  in  acetone  on  two 
consecutive days (days 1  and  2).  Challenge  was 
performed on day 6  by  application  of 30  j_lL  of 
2%  oxazolone  to  both  ears,  p-sitosterol  and 
dexamethasone were  applied  (20  (.iL)  to  right 
ears 6 h after challenge (single  application) and 
24,  48,  72 and  96  h  after  challenge  (repeated 
dosage). Ear  thickness measurements  of  treated 
and control groups  were done  with a micrometer 
(Mitutoyo  series  293)  24  and  102  h  after 
challenge and just  before drug application.  The 
102 h measurement  was  performed immediately 
before sacrifice.  Swelling was  assessed in terms 
of mean  thickness increase of  each  ear. 
Myeloperoxidase  assay 
It  was performed  according  to  Young  and  De 
Young  (15).  Each  biopsy,  placed  in  an 
Eppendorf  tube  containing  0.75  mL  of  0.5% 
HTAB  in  80  mM  sodium  phosphate  buffer 
(pH=5.4),  was  homogenised  (45  s).  The 
homogenate  was  centrifuged  and  the 
supernatant  (30  ^L)  was assayed  by  mixing  it 
with 20 [xL  of TMB  18.4 mM  and 15 ^L of H2O2 
0.017 %  in a 96-well microtiter plate. The  mixture 
was  incubated  for  3  min  at  37  °C.  Enzyme 
activity  was determined colorimetrically  using  a 
Labsystem Multiscan MCC/340 plate  reader set 
to measure  absorbance  at 620  nm. 
Statistics 
Oedemas  are expressed as mean  ± S.E.M. and 
inhibition  percentages  arise  from  differences 
between  treated  and  non-treated  tissues,  and 
are  referred  to  the control treated  only with the 
inflammatory agent.  Percentages of inhibition  of 
eicosanoids  production  are  shown as  mean ± 
S.E.M.  of  three  or  more  independent 
experiments,  and  every  experiment  was 
performed  in  duplicate.  The inhibition  of 5-LOX 
activity is expressed as percentages  with respect 
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to  the  control,  which  includes  LTB4  and  5(S)- respectively.  Statistical  evaluation  was 
HETE. Inhibition of COX-1 and 12-LOX  activities  performed  by ANOVA  followed  by  Dunnett's  t-
is  expressed as percentages with respect to the  test  for  multiple  comparisons  using  Graph-Pad 
control  of  12(S)-HHTrE  and  12(S)-HETE)  InStat software. 
Table 1.  Effects of p-sitosterol  at  100 ug/mL on the activity  of different enzymes  of the AA  pathway. 5-
LOX  activity measured  by  the release of LTB4; COX-1 activity measured  as 12(S)-HHTrE  release; 12-LOX 
activity  measured as 12(S)-HETE release. Values are mean  + S.E.M.  (n = 3);  **  P  < 0.01.  (Dunnett's t-
test).  As references we  used ethanol extract of gum  of Boswellia serrata (Bs) (20 ug/mL) for the 5-LOX 
activity,  Piroxicam (15 uM)  for COX-1 activity and  nor-dihydroguayaretic acid (NDGA)  (10 uM)  for 12-LOX 
activity. 
Table 2:  Effects of p-sitosterol  (0.5 mg/ear) and dexamethasone  (0.05 mg/ear) on induced DTH  in  mice. 
Values  are mean  ± S.E.M. (n =  6); ** P<  0.01. (Dunnett's f-test) compared  with control. 
AT±E 
Compound  24  h  48  h  72  h  96  h  102  h 
Control  232,5±9,2  176,6±12,8  227,3±14,2  228,8+13,8  226,1±24,5 
P-sitosterol  162,9±10,9  164,6±12,9  187,6±8,0  214,3±16,9  250,2±13,9 
Dexamethasone  80,5±8,2**  58,5±9,8**  37,7±26,9**  57,2±15,1**  83,7±15,2** 
(AT) Thickness  variation (mm  x 10'3); ** P<  0,01  (Dunett's  t Test) 
Compound  %  Inhibition 
24  h  48  h  72  h  96  h  1021 
p-sitosterol  30  7  17  6  -11 
Dexamethasone  65  67  77  75  63 
Table  3. Effects of p-sitosterol I  and  dexamethasone  on  the  activity of MPO  in ear  biopsies. 
Compound  Absorbance  %  Activity MPO 
Control  1,537 ±0,114  100 
P-sitosterol  1,376  +  0,096  90 
Dexamethasone  0,837  ±  0,167**  46 
**p<0,01 (Dunett's  t Test) 
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Results  and  Discussion 
p-sitosterol  did  not  show  any  cytotoxicity  in 
human PMN  at a dose of 200 u.g/mL in  the MTT 
assay  (data  not  shown).  The  results  of  the 
models  of eicosanoid release are summarised  in 
Table  1.  p-sitosterol  did  not  inhibit  LTB4 
production neither the production of 5(S)-HETE. 
It  also  failed  to  inhibit  12(S)-HHTrE  release,  a 
valid  marker  of  the  COX-1  activity  (16).  The 
obtained  results  in  the  oxazolone-induced 
contact  dermatitis  are  showed in  Table  2.  The 
extract inhibited the oedema  at 24 hours but  this 
effect  was not  maintained  until  the  end  of  the 
assay.  It  did  not  inhibit  the  leukocyte  infiltration 
measured  as  myeloperoxidase  activity  in 
biopsies (Table 3). 
In  the  in  vivo  model  of  DTH,  p-sitosterol  has 
been  shown  to  inhibit  the  oedema  in  the 
oxazolone-induced  DTH  model  in  the  24  first 
hours.  The  inhibition  is  of  pharmacological 
significance  in  accordance with  Young and  De 
Young  (15), which established that in  this model 
NSAIDs  only inhibit  in  a extend of 30-40%  at 24 
h.  The subjacent  mechanisms  of  DTH models 
are  based  on  the  modification  of  endogenous 
proteins  by  covalent  binding  of  haptens. 
Oxazolone  acts  as  a  hapten  that  reacts 
covalently  with  proteins  to  lead  to  an  antigen-
protein complex  that is target  of  T-lymphocytes. 
The  Langerhan'  cells recognize  this complex  and 
migrate  from  epidermis  to  lymph  nodes,  thus 
initiating  a  specific  immune  response.  After  a 
second  contact  with the hapten, an inflammatory 
reaction  appears  by  inducing  macrophage 
cytokine release and PGE2  synthesis during the 
respective  early  vascular  and  late  cellular 
phases  of  inflammation  (17).  It  is  possible, 
however,  that  the  response  to  oxazolone  may 
partly evolve on a different pathway independent 
of  interleukin-4 (18). The  results indicate that  this 
compound can  participate  in  the  inhibition  of a 
cell-mediated oedema  during its  earlier stage.  If 
(3-sitosterol  does  not  inhibit  the  COX pathway 
responsible  for  PGE2  synthesis  other 
mechanisms  must  be  considered. 
As  conclusion, we  here  establish for  first time  the 
in  vivo  anti-inflammatory  activity  of  the  p-
sitosterol  in  a  model  of  delayed  contact 
dermatitis.  The  results  indicate  that  this 
compound  can  modulate  a  cell-mediated 
oedema  without any short term in  vitro  effect  in 
the  arachidonate  pathway  of  intact  cells.  The 
ubiquity  of  this  compound  can  explain,  and 
predict,  the effect  of many plant extracts  in  this 
model,  and  so  this  data  could  be  of  help  in 
dereplication processes. 
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